Vesugen Dosage, Protocol & What People Actually Use It For

Quick refresher — what Vesugen is

Vesugen is the three-amino-acid peptide Lys-Glu-Asp, abbreviated KED. It comes from the Khavinson school of peptide bioregulators developed at the St. Petersburg Institute of Bioregulation and Gerontology. It was synthesized to mimic the active fragment of vascular-tissue cytomedins — the family of short peptides extracted from healthy vascular tissue that, in animal work, preserved aging endothelial function.

If you want the full mechanism and evidence base — gene expression effects, the MKI67 promoter binding, the 2024 induced-neuron dendrite study, the epigenetic decondensation finding — see the main Vesugen explainer. This article focuses on the practical questions: how it is dosed, how it is taken, what side effects are documented, and how people in the bioregulator community actually use it.

The three forms: capsule, sublingual, injection

Vesugen is sold and used in three formulations. Each has a different dose calculus, a different bioavailability assumption, and a different practical use case.

Oral capsule (the most common form). Sold by the Russian manufacturer in 200 microgram per capsule packaging, typically dispensed in 60-capsule packs. Standard course is one capsule taken twice daily, in the morning and evening, 10–15 minutes before food, for 20 to 30 days. Total daily dose works out to 400 micrograms of active peptide. The "10 mg/day" number that appears on many resale sites usually refers to total formulation weight (with excipients), not pure peptide content. Capsule Vesugen is the format the Russian clinical work has been done on.

Sublingual liquid. Dispensed as a 10 ml dropper bottle, with concentrations that vary by manufacturer; many products are formulated to deliver roughly 200–500 micrograms of active peptide per drop or per pump. Held under the tongue for 30–60 seconds before swallowing, the rationale being that direct mucosal absorption bypasses gut enzymes that may cleave the tripeptide before it can be absorbed intact. The bioavailability advantage is mechanistically plausible — buccal absorption of short peptides has decent literature support — but no head-to-head pharmacokinetic comparison of sublingual vs oral capsule Vesugen has been published in peer review.

Reconstituted injection. Sold as a lyophilized powder vial, most commonly 20 mg of synthesized peptide, reconstituted with bacteriostatic water. Used subcutaneously by a small subset of the bioregulator-using community. Daily doses in Western informal protocols range widely (typical 500–2000 micrograms per day). The injectable route has the highest bioavailability and the strongest dose-control, but it is also the form with the least direct clinical data — the published Meshchaninov study used oral dosing — and the form most likely to fall outside the legal/regulatory category in many jurisdictions.

The standard dose — and where 10 mg/day comes from

The Russian clinical convention — and the dose used in the Meshchaninov 2015 polymorbid-elderly trial — was the standard capsule protocol: 200 micrograms twice daily, oral, before meals, for a course of 20 to 30 days.^[1] That is the dose with the most direct evidence behind it.

The "10 mg/day" figure that shows up in many online Vesugen discussions and search queries is a quirk of product labeling. Most retail Vesugen capsules contain a total formulation weight of 10 mg per capsule, of which 200 micrograms (0.2 mg) is the active KED peptide and the remainder is microcrystalline cellulose and other excipients. Two capsules per day delivers 20 mg of total formulation weight — sometimes phrased as "10 mg of Vesugen" by people quoting the label rather than the active-ingredient content. Both are technically correct; both refer to the same standard protocol.

Injectable doses in the informal Western peptide community are usually quoted in micrograms of active peptide, and run higher than the oral equivalent — partly because injection bypasses the first-pass enzymatic loss that the oral and sublingual routes are exposed to. Typical informal subcutaneous protocols are in the 500–2000 mcg/day range. That has no direct clinical-trial foundation. The published Russian work used the oral route.

The dose with actual clinical evidence behind it is 200 micrograms of pure KED, taken orally, twice a day, before meals, for a 20-day course. Everything else is extrapolation.

Course length and cycle structure

Vesugen is not taken continuously. The standard Russian clinical convention is a 10- to 20-day active course, with the course repeated 2–3 times per year. The longer 30-day variant exists but is less common in the published clinical work. The cycling structure reflects the underlying premise of bioregulator therapy: short peptide signals do not need to be continuously present to produce a remodeling effect on the target tissue. Once the signal has been delivered for the duration required to shift gene expression, the cell carries the effect forward.

The interval between courses matters more than people often appreciate. The Russian convention is typically 3 to 6 months between courses. Compressing that interval — taking back-to-back courses with no gap — does not appear to add benefit and is not the protocol the clinical data supports.

In practice, a typical year on Vesugen for someone using it as a preservation strategy looks like: 20-day course in late winter or early spring, 4-month gap, 20-day course in summer, 4-month gap, 20-day course in late autumn. Three courses, roughly 60 dosing days, the remainder of the year off.

What people actually use Vesugen for

Looking across the Russian clinical literature, the bioregulator practitioner community, and the informal peptide community in the West, the most common practical uses cluster around four themes:

• Vascular preservation in middle-aged and older adults with cardiovascular risk factors. Family history of premature atherosclerosis, measurable endothelial dysfunction on testing, post-coronary-event maintenance, or persistent peripheral vascular symptoms. This is the most mechanistically aligned use case and the one closest to the original Khavinson-school intent.
• Post-stroke and post-TIA recovery support. The Meshchaninov 2015 paper specifically enrolled patients with organic brain syndrome of vascular or traumatic origin in remission, and Vesugen was reported to slow biological-age markers in that group.^[1] Russian clinical practice has used Vesugen in this setting for years, typically alongside neurotropic peptides.
• Cognitive support in elderly individuals with vascular contribution to cognitive slowing. The Khavinson 2021 review reported that oral KED improved memory and attention in elderly individuals with functional CNS disorders.^[2] The molecular target list — p16, p21, IGF1, APOE — overlaps meaningfully with vascular contributions to mild cognitive impairment.
• Generalized longevity stacks. A meaningful fraction of Vesugen use in the West is not for any specific tissue concern but as part of a multi-peptide longevity protocol — often layered onto Epitalon and Thymalin as foundation peptides. The mechanistic case for this is weaker; without a vascular or neural target, the benefit case is more theoretical than supported.

Notable absences from the actual evidence base: Vesugen as a daily multivitamin, Vesugen as performance enhancer for healthy young athletes, Vesugen for cosmetic skin effects, Vesugen as a substitute for blood-pressure medication. None of those uses are supported by what the published data shows.

Side effects and what to watch for

The clinical safety data on Vesugen is genuinely small. The 32-patient Meshchaninov 2015 series reported no serious adverse events and no significant changes in standard hematology, hepatic, or renal panels at oral 200-mcg-twice-daily dosing.^[1] The mechanistic work consistently shows activity at nanomolar concentrations — orders of magnitude below where conventional small-molecule toxicity typically emerges. The molecule itself, structurally, is just three amino acids: lysine, glutamic acid, and aspartic acid. Once cleaved, the breakdown products are amino acids the body handles routinely from any protein meal.

Across the informal community use and Russian clinical reports, the mild side effects most commonly mentioned are:

• Transient mild headache or pressure sensation in the first few days of a course, typically resolving without intervention.
• Sleep changes — usually improved sleep quality, but a minority of users report initial insomnia or vivid dreaming, particularly with evening dosing. Switching the second dose earlier in the afternoon resolves this for most.
• Mild gastrointestinal sensitivity if taken without sufficient water or too close to a fatty meal.
• Local injection-site reactions in the subcutaneous route — minor redness, occasional bruising. Standard injection-technique issues, not a peptide-specific effect.

Two more meaningful signals from the published evidence deserve their own attention.

The CD34+ finding worth knowing about

In the same Meshchaninov 2015 paper, the investigators measured circulating CD34+ hematopoietic stem cells before and after treatment with Vesugen and Pinealon.^[1] They reported a significant decrease in CD34+ cells after the peptide course, which they interpreted as inhibition of hemopoiesis. They also reported a prooxidant signal by chemiluminescence — meaning the peptides did not act as antioxidants in this assay and may have a modest oxidative effect.

How to weigh these findings honestly: this is a single 32-patient series in a polymorbid elderly population, published in Russian, without Western replication. The CD34+ suppression could be a real biological effect, an artifact of the polymorbid sample, or a measurement-timing issue. The signal has not been replicated or refuted in the 11 years since.

What I would do with it: avoid Vesugen if you have any active hematological concern (cytopenias, post-chemotherapy recovery, myelodysplasia history, hematologic malignancy in remission), and have a CBC before and after a first course if you have any underlying risk factor. The mechanistic plausibility of mild CD34+ modulation by an epigenetically-active peptide is not zero, and the absence of replication is itself information.

Who should not take Vesugen

Based on the mechanism, the safety signals, and the publication-level evidence, the populations who should not take Vesugen without specialist supervision (or at all) are:

• People with active hematological disease — cytopenias, hematologic malignancy in active treatment or recent remission, myelodysplastic syndromes, or anyone post-chemotherapy in the hematopoietic recovery phase. The CD34+ signal makes the risk-benefit calculus uncertain.
• People with active cancer of any type — not because Vesugen has shown tumor-promoting effects (it has not), but because the molecule modulates IGF1 and proliferation-related gene expression, and the long-term cancer safety data simply does not exist. The Khavinson school's position is that bioregulators preserve homeostasis rather than drive proliferation, but this has not been formally established in cancer-affected populations.
• Pregnant or breastfeeding individuals — no safety data, no developmental data, no exposure rationale.
• Children and adolescents — outside the original therapeutic intent (aging tissue preservation), no pediatric safety data.
• Anyone with a known allergy to short peptides or to the capsule excipients in the oral formulation.
• Anyone on actively-titrated immunosuppression or active anticoagulation without a treating-physician review — the mechanistic interaction risk is plausible but not characterized.

Stacking with other bioregulators

Vesugen is rarely used alone in the Russian clinical tradition. The Khavinson school's framework, summarized in the 2025 Arutjunyan review,^[5] is that bioregulators work in tiers. The foundation is the immune and pineal axes — Thymalin (thymic, immune) and Epitalon (pineal, circadian and chromatin). Organ-specific peptides like Vesugen layer onto that foundation by indication: Cortagen for cortical cognitive presentations, Pinealon for memory and attention, Vesugen for vascular and cerebrovascular concerns, Livagen for hepatic, Crystagen for general immune modulation, and so on.

Two stacking patterns appear repeatedly in the published Russian work and in Western community use:

• Vesugen + Pinealon for vascular cognitive concerns — the combination used in the Meshchaninov 2015 trial. The rationale is straightforward: Vesugen targets the vascular substrate, Pinealon targets the neuronal substrate, and the two work on overlapping but non-redundant gene-expression endpoints. Both are short peptides delivered orally on the same daily schedule.
• Foundation course (Thymalin + Epitalon) → then organ-specific (Vesugen or other) overlay — for general longevity-oriented use. Foundation courses run twice yearly, organ-specific overlays added by need. The framework prioritizes immune and chromatin maintenance before tissue-specific interventions.

What the published data does not support is layering five, six, or eight peptides simultaneously in one course. The original clinical work used one or two peptides per course. The "polypeptide stack" approach popular in some Western longevity communities is an extrapolation, not a tested protocol.

Practical position

After looking honestly at the available evidence and the practical-use questions people actually search for, here is where I land on Vesugen dosing.

• Use the oral capsule route if you are starting. It is the form with direct clinical-trial data, the lowest entry threshold, and the cleanest legal status in most jurisdictions. 200 micrograms twice daily before meals for a 20-day course. Repeat 2–3 times per year.
• The sublingual liquid is a reasonable convenience choice once you know how you respond. Mechanistically plausible bioavailability advantage, no direct comparison data. Useful if oral capsule timing relative to meals is impractical.
• Skip injectable Vesugen unless you have specific reason and clinical supervision. The route has the least direct clinical evidence behind it, the least standardized dose-finding, and the most regulatory exposure.
• Do a CBC before and after your first course if you have any hematological consideration. The CD34+ signal in the published data is small and not replicated, but it is the only consistent flag in the safety literature.
• Build Vesugen onto a foundation, not into a stack. If you are not running Epitalon or Thymalin as your baseline bioregulator protocol, the case for adding Vesugen on top is weaker. The Khavinson framework is foundation-first.
• Do not exceed the cycle structure. 10–20 days on, 3–6 months off, 2–3 courses per year. Compressing the schedule or running it continuously is not what the protocol calls for and is not what the evidence supports.

The dose is small. The course is short. The interval is long. That is a feature of bioregulator pharmacology, not a limitation — and treating it that way is the difference between using Vesugen as the literature describes it and using it the way the marketing implies.

References

1. Meshchaninov VN, Tkachenko EL, Zharkov SV, et al. Effect of synthetic peptides on aging of patients with chronic polymorbidity and organic brain syndrome of the central nervous system in remission. Advances in Gerontology. 2015;28(1):62-67.
2. Khavinson VK, Lin'kova NS, Umnov RS. Peptide KED: Molecular-Genetic Aspects of Neurogenesis Regulation in Alzheimer's Disease. Bulletin of Experimental Biology and Medicine. 2021;171(2):190-193.
3. Ashapkin V, Khavinson V, Shilovsky G, et al. Gene expression in human mesenchymal stem cell aging cultures: modulation by short peptides. Molecular Biology Reports. 2020;47(6):4323-4329.
4. Kraskovskaya N, Linkova N, Sakhenberg E, et al. Short Peptides Protect Fibroblast-Derived Induced Neurons from Age-Related Changes. International Journal of Molecular Sciences. 2024;25(21):11363.
5. Arutjunyan A, et al. Peptide Regulation of Ageing: From Experiment to Practice. Current Aging Science. 2025.
6. Wellness Radar Editorial. Vesugen (KED): The Vascular Bioregulator Explained. Wellness Radar. 2026.